Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.

Solomon TadesseLaychiluh BantieKhamis TomusangeMingfeng YuSaiful IslamNataliya BykovskaBenjamin NollGe ZhuPeng LiFrankie LamMalika KumarasiriRobert MilneShudong Wang

Published in: British journal of pharmacology (2018)

We have identified unique and new inhibitors of CDK4/6 as potential drug candidates. Compound 91 represents an ideal candidate for further development as targeted cancer therapy.

Keyphrases

cancer therapy
cell cycle
drug delivery
small molecule
high throughput
human health
adverse drug
climate change